Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer

Figure 5

The ROC curves of anti-GRP78 antibody in the subgroup analysis. (a) Test cohort GC (stage I-II) vs. NH. (b) Test cohort GC (stage III-IV) vs. NH. (c) Test cohort GC (tumor size <5 cm) vs. NH. (d) Test cohort GC (tumor size ≥5 cm) vs. NH. (e) Test cohort GC (LM) vs. NH. (f) Test cohort GC (no LM) vs. NH. (g) Test cohort GC (poor differentiation) vs. NH. (h) Test cohort GC (moderate and high) vs. NH. (i) Validation cohort GC (stage I-II) vs. NH. (j) Validation cohort GC (stage III-IV) vs. NH. (k) Validation cohort GC (tumor size <5 cm) vs. NH. (l) Validation cohort GC (tumor size ≥5 cm) vs. NH. (m) Validation cohort GC (LM) vs. NH. (n) Validation cohort GC (no LM) vs. NH. (o) Validation cohort GC (poor differentiation) vs. NH. (p) Validation cohort GC (moderate and high) vs. NH.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)